7 results match your criteria: "Houston (J.B.-B.); and the University of California San Francisco Health[Affiliation]"
FAIRS - A Framework for Evaluating the Inclusion of Sex in Clinical Algorithms.
N Engl J Med
January 2025
From the University of Maryland School of Medicine, Baltimore (K.E.G.); the University of Maryland Carey School of Law, Baltimore (D.E.H.); the University of Maryland Institute for Health Computing, North Bethesda (K.E.G.); the Baylor College of Medicine, Houston (J.B.-B.); and the University of California San Francisco Health, San Francisco (R.F.R.).
Prehospital tranexamic acid is associated with a survival benefit without an increase in complications: Results of two harmonized randomized clinical trials.
J Trauma Acute Care Surg
November 2024
From the Division of Trauma and General Surgery, Department of Surgery (M.M., J.K.D., J.B.B., M.D.N., J.L.S.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Surgery (M.S.), Oregon Health and Science University, Portland, Oregon; Department of Surgery (S.R.), University of Chicago, Chicago, Illinois; Department of Emergency Medicine (F.X.G.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Surgery (B.C.), University of Texas Health Houston, Houston; Department of Surgery (B.J.E.), University of Texas Health San Antonio, San Antonio, Texas; Department of Surgery (R.N.), University of Utah, Salt Lake City, Utah; and Department of Surgery (G.A.V., T.O., B.J., J.B.B.), University of Arizona, Tucson, Arizona.
Introduction: Recent randomized clinical trials have demonstrated that prehospital tranexamic acid (TXA) administration following injury is safe and improves survival. However, the effect of prehospital TXA on adverse events, transfusion requirements, and any dose-response relationships require further elucidation.
Methods: A secondary analysis was performed using harmonized data from two large, double-blinded, randomized prehospital TXA trials.
Article Synopsis
- High-risk multiple myeloma (MM) patients, especially those who relapse early after therapy, benefit significantly from the combination of daratumumab with either bortezomib/dexamethasone or lenalidomide/dexamethasone.
- In the CASTOR and POLLUX studies, daratumumab significantly improved progression-free survival (PFS) and overall survival (OS) for relapsed/refractory MM patients across both early and late relapse groups.
- Despite not fully overcoming the risks associated with early relapse, the findings support using daratumumab for patients with one prior line of therapy, enhancing complete response rates and minimal residual disease negativity.
Patients with both traumatic brain injury and hemorrhagic shock benefit from resuscitation with whole blood.
J Trauma Acute Care Surg
December 2023
From the Center for Translational Injury Research (G.E.H., J.B.B., B.T., K.M.M., C.C.M., L.S.K., B.A.C.), Department of Surgery (G.E.H., J.B.B., B.T., K.M.M., C.C.M., L.S.K., B.A.C.), and Center for Surgical Trials and Evidence-based Practice (G.E.H., K.M.M., L.S.K.), McGovern Medical School at the University of Texas Health Science Center, Houston, Texas.
Background: Hemorrhagic shock in the setting of traumatic brain injury (TBI) reduces cerebral blood flow and doubles mortality. The optimal resuscitation strategy for hemorrhage in the setting of TBI is unknown. We hypothesized that, among patients presenting with concomitant hemorrhagic shock and TBI, resuscitation including whole blood (WB) is associated with decreased overall and TBI-related mortality when compared with patients receiving component (COMP) therapy alone.
View Article and Find Full Text PDFGlycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
N Engl J Med
September 2022
From the Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston (D.M.N., M.E.L., D.J.W.); the Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville (J.M.L., N.M.B., H.K.-S., N.Y.), and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda (H.B.B.) - both in Maryland; the Section of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston (A.B.); the Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill (J.B.B.); the Cincinnati Veterans Affairs (VA) Medical Center, University of Cincinnati College of Medicine, Cincinnati (R.M.C.); the Division of Endocrinology and Diabetes and the Fleischer Institute for Diabetes and Metabolism, Albert Einstein College of Medicine, Bronx, NY (J.P.C.); the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, VA Puget Sound Health Care System, University of Washington, Seattle (S.E.K.); the Division of Endocrinology, Metabolism, and Diabetes, University of Colorado School of Medicine, and the VA Eastern Colorado Health Care System - both in Aurora (N.R.); and the Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland (M.T.).
Background: The comparative effectiveness of glucose-lowering medications for use with metformin to maintain target glycated hemoglobin levels in persons with type 2 diabetes is uncertain.
Methods: In this trial involving participants with type 2 diabetes of less than 10 years' duration who were receiving metformin and had glycated hemoglobin levels of 6.8 to 8.
Prehospital plasma in injured patients is associated with survival principally in blunt injury: Results from two randomized prehospital plasma trials.
J Trauma Acute Care Surg
January 2020
From the Department of Surgery (K.M.R., A.H., J.B.B., B.S.Z., M.D.N., J.L.S.), University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Surgery (H.B.M., A.S., E.E.M., M.P.C.), University of Colorado and Denver Health Medical Center, Denver, Colorado; Department of Emergency Medicine (F.X.G.), University of Pittsburgh, Pittsburgh, Pennsylvania; US Army Institute of Surgical Research (A.E.P.), JBSA Fort Sam Houston, San Antonio, Texas; Department of Surgery (B.J.D.), University of Tennessee Health Science Center, Knoxville; Department of Surgery (R.S.M.), Vanderbilt University Medical Center, Nashville, Tennessee; University of Louisville (B.G.H.), Louisville, Kentucky; MetroHealth Medical Center (J.A.C.), Case Western Reserve University, Cleveland, Ohio; Department of Surgery (H.A.P.), University of Texas Southwestern, Parkland Memorial Hospital, Dallas, Texas; Department of Pathology (M.H.Y.), University of Pittsburgh and Institute for Transfusion Medicine, Pittsburgh, Pennsylvania.
Introduction: Recent evidence demonstrated that prehospital plasma in patients at risk of hemorrhagic shock was safe for ground transport and resulted in a 28-day survival benefit for air medical transport patients. Whether any beneficial effect of prehospital plasma varies across injury mechanism remains unknown.
Methods: We performed a secondary analysis using a harmonized data set derived from two recent prehospital plasma randomized trials.
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
N Engl J Med
December 2017
From the University of Colorado Denver, Aurora (S.K.G.); the University of California at San Diego, San Diego (R.R.H.); Lexicon Pharmaceuticals, The Woodlands (P.B., D.G.-P., P.L., P.S.), the University of Texas Southwestern Medical Center, Dallas (D.K.M.), and Baylor College of Medicine and Texas Children's Hospital, Houston (J.A.K.) - all in Texas; the Diabetes Research Center, University of North Carolina School of Medicine, Durham (J.B.B.); the University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, United Kingdom (M.J.D.); the University of Sydney, Sydney (G.R.F.); University Campus Bio-Medico of Rome, Rome (P.P.); Vall d'Hebron Research Institute, Barcelona, and CIBERDEM-Instituto de Salud Carlos III, Madrid (R.S.); Diabetes Center Auf der Bult, Hannover Medical School, Hannover, Germany (T.D.); and the University of Southern California, Los Angeles (A.P.).
Article Synopsis
- - The study aimed to test the safety and effectiveness of sotagliflozin, an oral medication, when combined with insulin therapy in patients with type 1 diabetes who often struggle to control their blood sugar levels.
- - In a phase 3 trial involving 1402 patients over 24 weeks, the group taking sotagliflozin showed a significantly higher success rate in achieving target blood sugar levels without severe hypoglycemia compared to the placebo group.
- - Results indicated improvements in additional health metrics, such as weight loss and lower blood pressure in the sotagliflozin group; however, there was an increased rate of diabetic ketoacidosis in that group compared to the placebo.